vincristine
E436082
World Health Organization essential medicine
antineoplastic agent
chemotherapy medication
mitotic inhibitor
vinca alkaloid
Vincristine is a chemotherapy medication, specifically a vinca alkaloid, widely used in combination regimens to treat various cancers including lymphomas and leukemias.
All labels observed (1)
| Label | Occurrences |
|---|---|
| vincristine canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T4392581 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: vincristine Context triple: [non-Hodgkin lymphoma, hasCommonDrug, vincristine]
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
cyclophosphamide
Cyclophosphamide is a widely used alkylating chemotherapy and immunosuppressive drug commonly employed in the treatment of cancers and autoimmune diseases.
-
C.
bortezomib
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
-
D.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
E.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: vincristine Target entity description: Vincristine is a chemotherapy medication, specifically a vinca alkaloid, widely used in combination regimens to treat various cancers including lymphomas and leukemias.
-
A.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
B.
cyclophosphamide
Cyclophosphamide is a widely used alkylating chemotherapy and immunosuppressive drug commonly employed in the treatment of cancers and autoimmune diseases.
-
C.
bortezomib
Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
-
D.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
E.
Xeloda
Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
- F. None of above. chosen
Statements (57)
| Predicate | Object |
|---|---|
| instanceOf |
World Health Organization essential medicine
ⓘ
antineoplastic agent ⓘ chemotherapy medication ⓘ mitotic inhibitor ⓘ vinca alkaloid ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| contraindicatedIn | patients with demyelinating Charcot–Marie–Tooth disease ⓘ |
| discoveredBy | Eli Lilly and Company researchers NERFINISHED ⓘ |
| hasATCCode | L01CA02 ⓘ |
| hasBlackBoxWarning | fatal if given intrathecally ⓘ |
| hasBrandName | Oncovin NERFINISHED ⓘ |
| hasCASNumber | 57-22-7 ⓘ |
| hasChemicalClass |
dimeric indole–indoline alkaloid
ⓘ
indole alkaloid ⓘ tubulin inhibitor ⓘ |
| hasDoseLimitingToxicity | neurotoxicity ⓘ |
| hasMajorAdverseEffect |
SIADH
NERFINISHED
ⓘ
alopecia ⓘ constipation ⓘ jaw pain ⓘ myelosuppression ⓘ paralytic ileus ⓘ peripheral neuropathy ⓘ |
| hasMechanismOfAction |
arrests cells in metaphase
ⓘ
binds to tubulin ⓘ disrupts mitotic spindle formation ⓘ inhibits microtubule polymerization ⓘ |
| hasMolecularFormula | C46H56N4O10 ⓘ |
| hasOrigin |
Catharanthus roseus
ⓘ
Madagascar periwinkle NERFINISHED ⓘ |
| hasRouteOfAdministration |
intravenous
ⓘ
intravenous infusion ⓘ intravenous push ⓘ |
| hasUNII | OL437M7FCK ⓘ |
| isAdministeredWith | careful dose capping in obese patients ⓘ |
| metabolizedBy |
CYP3A4
NERFINISHED
ⓘ
CYP3A5 NERFINISHED ⓘ |
| pregnancyCategory | D (risk to fetus) ⓘ |
| substrateOf | P-glycoprotein NERFINISHED ⓘ |
| usedForTreatmentOf |
Burkitt lymphoma
NERFINISHED
ⓘ
Ewing sarcoma NERFINISHED ⓘ Hodgkin lymphoma NERFINISHED ⓘ Wilms tumor NERFINISHED ⓘ acute lymphoblastic leukemia ⓘ acute myeloid leukemia ⓘ gestational trophoblastic neoplasia ⓘ multiple myeloma ⓘ neuroblastoma ⓘ non-Hodgkin lymphoma NERFINISHED ⓘ rhabdomyosarcoma ⓘ small cell lung cancer ⓘ |
| usedInRegimen |
ABVD chemotherapy regimen
NERFINISHED
ⓘ
CHOP chemotherapy regimen NERFINISHED ⓘ MOPP chemotherapy regimen NERFINISHED ⓘ R-CHOP chemotherapy regimen NERFINISHED ⓘ VAC chemotherapy regimen NERFINISHED ⓘ VCR–prednisone–L-asparaginase regimens NERFINISHED ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: vincristine Description of subject: Vincristine is a chemotherapy medication, specifically a vinca alkaloid, widely used in combination regimens to treat various cancers including lymphomas and leukemias.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.